The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
AVALUZ study: First line with bevacizumab in combination with paclitaxel (P) and gemcitabine (G) in patients with HER2-negative or recurrent mBC: OS analysis.
Javier Salvador
No relevant relationships to disclose
Eva M. Ciruelos
No relevant relationships to disclose
Manuel Codes
No relevant relationships to disclose
Ana Jaen
No relevant relationships to disclose
Miquel Gil
No relevant relationships to disclose
Antonio Galan
No relevant relationships to disclose
Adolfo Murias
No relevant relationships to disclose
Carlos Jara-Sanchez
No relevant relationships to disclose
Juan De la Haba- Rodriguez
No relevant relationships to disclose
Jose Manuel Baena
No relevant relationships to disclose
Maria Jose Villanueva Silva
No relevant relationships to disclose
Juan L. Bayo
No relevant relationships to disclose
Isabel Blancas
No relevant relationships to disclose
Encarnacion Gonzalez
No relevant relationships to disclose
Diego Perez
No relevant relationships to disclose
Jose Ramón Mel
No relevant relationships to disclose
Luis Manso
No relevant relationships to disclose